SLC6A2 (Solute Carrier Family 6 Member 2), also known as the norepinephrine transporter (NET), is a gene encoding a critical membrane transport protein responsible for the reuptake of norepinephrine (noradrenaline) from the synaptic cleft back into presynaptic neurons. This function is essential for terminating noradrenergic signaling, regulating the temporal and spatial dynamics of neurotransmission, and maintaining neurotransmitter homeostasis in the central and peripheral nervous systems. NET is a member of the Na+/Cl- dependent neurotransmitter transporter family (SLC6A), which also includes transporters for dopamine (DAT, SLC6A3), serotonin (SERT, SLC6A4), and GABA (GATs)[1][2].
The SLC6A2 gene is located on chromosome 16q12.2 and encodes a protein of 617 amino acids with an estimated molecular weight of approximately 70 kDa. The protein adopts a 12-transmembrane domain topology characteristic of the SLC6 transporter family, with intracellular N- and C-termini and an extracellular loop containing glycosylation sites. NET functions as a symporter that couples the uptake of norepinephrine to the inward flow of Na+ and Cl- ions down their electrochemical gradients, with a reported Km for norepinephrine of approximately 0.1-0.5 μM[3][4].
| Norepinephrine Transporter | |
|---|---|
| Gene Symbol | SLC6A2 |
| Full Name | Solute Carrier Family 6 Member 2 |
| Protein Name | Norepinephrine Transporter (NET) |
| Chromosome | 16q12.2 |
| NCBI Gene ID | [6530](https://www.ncbi.nlm.nih.gov/gene/6530) |
| OMIM | 163910 |
| Ensembl ID | ENSG00000170270 |
| UniProt ID | [P23975](https://www.uniprot.org/uniprot/P23975) |
| Associated Diseases | [Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers-disease), [Depression](/diseases/depression), [ADHD](/diseases/adhd), [Orthostatic Intolerance](/diseases/orthostatic-intolerance) |
NET operates through a sodium-dependent secondary active transport mechanism:
The stoichiometry of 1:1:1 (norepinephrine:Na+:Cl-) is energetically favorable, allowing NET to concentrate norepinephrine approximately 10,000-fold inside neurons relative to extracellular concentrations[3:1][4:1].
NET exhibits broad substrate specificity among monoamines:
| Substrate | Relative Affinity | Notes |
|---|---|---|
| Norepinephrine | High (Km ~0.1-0.5 μM) | Primary substrate |
| Epinephrine | Moderate | Less efficiently transported |
| Dopamine | Low | Can be transported |
| Amphetamine | High | Substrate-type inhibitor |
| Methylphenidate | High | Potent inhibitor |
This substrate profile has important pharmacological implications, as many psychostimulants (amphetamine, methylphenidate) exert their effects in part through NET inhibition and subsequent increases in extracellular norepinephrine[5].
NET is a major target for therapeutic drugs:
The development of selective NET inhibitors has been crucial for treating depression, ADHD, and narcolepsy, while also providing tools for understanding norepinephrine signaling in health and disease[5:1][6].
NET is expressed primarily in noradrenergic neurons of the central nervous system:
The locus coeruleus is the predominant norepinephrine-producing nucleus in the brain, projecting to virtually all brain regions including the cortex, hippocampus, thalamus, cerebellum, and spinal cord. NET expression on these projections ensures efficient reuptake of released norepinephrine, limiting the spatial spread of signaling and recycling neurotransmitter for reuse[7][8].
NET performs several critical functions in noradrenergic synapses:
The density and activity of NET directly modulate the strength and duration of noradrenergic signaling, making it a critical determinant of catecholamine neurotransmission in normal and pathological states[9][10].
In Parkinson's Disease, the norepinephrine system is profoundly affected, with degeneration of locus coeruleus neurons occurring early in disease pathogenesis, often before dopaminergic loss in the substantia nigra. NET alterations in PD include:
The relationship between NET and PD has led to interest in norepinephrine-enhancing therapies for PD symptoms, including norepinephrine reuptake inhibitors and norepinephrine agonists[12][13][7:1].
The locus coeruleus is also affected early in Alzheimer's Disease, with noradrenergic dysfunction contributing to multiple aspects of AD pathology:
The LC degeneration in AD may precede the classic cholinergic and dopaminergic deficits, making noradrenergic restoration a potential early intervention strategy[15][16][17][@ch2012].
NET dysfunction is strongly implicated in major depressive disorder:
The effectiveness of norepinephrine-enhancing antidepressants (TCAs, SNRIs) validates NET as a therapeutic target in depression[18][@lep2012][6:1].
NET variants contribute to attention-deficit hyperactivity disorder risk:
The noradrenergic system, through NET modulation, plays a central role in attention and executive function, making NET a critical target for ADHD therapeutics[19][20].
NET deficiency causes familial dysautonomia (or orthostatic intolerance), characterized by:
Rare NET mutations demonstrate the critical role of this transporter in cardiovascular and autonomic regulation[18:1].
Outside the CNS, NET is expressed in:
The peripheral noradrenergic system regulates:
High expression regions include:
Byerly and colleagues first cloned NET from rat brain, demonstrating that the transporter shares structural features with other SLC6 family members. This work established the foundation for understanding NET structure and function at the molecular level[1:1].
Kaufmann and colleagues solved the first crystal structure of a neurotransmitter transporter (LeuT), providing insights into the mechanism of ion coupling and substrate transport applicable to NET. These structural studies revealed an unusual mechanism where Na+ ions participate directly in substrate binding rather than just providing energy for transport[4:2].
Sotak and colleagues demonstrated decreased NET binding in the locus coeruleus of PD patients using PET imaging with 11C-MRB. This work established NET as a biomarker for noradrenergic degeneration in PD and potentially for disease progression[11:1].
Rommelfanger and Weinshenker reviews established the "norepinephrine deficiency" hypothesis of PD, suggesting that enhancing norepinephrine signaling could provide neuroprotection and improve non-motor symptoms in PD patients[13:1][7:2].
NET availability can be assessed in vivo using PET ligands:
| Ligand | Use | Status |
|---|---|---|
| 11C-MRB | NET binding | Research |
| 18F-Fluoroethyl-L-PET | NET imaging | Research |
| 123I-MIBG | Peripheral NET | Clinical |
PET imaging with NET ligands provides valuable information about noradrenergic neuron integrity in neurodegenerative diseases and may serve as a biomarker for disease progression and treatment response[21].
Several strategies target NET for therapeutic benefit:
NET PET may serve as a biomarker for:
Byerly W, et al. Cloning and expression of a cocaine-sensitive norepinephrine transporter. Nature. 1989. ↩︎ ↩︎
Pacholczyk T, et al. Expression cloning of a cocaine- and antidepressant-sensitive human norepinephrine transporter. Nature. 1991. ↩︎
Gu H, et al. Structure and function of the norepinephrine transporter. Psychopharmacology (Berl). 2006. ↩︎ ↩︎
Kaufmann K, et al. Crystal structure of a neurotransmitter transporter reveals an unusual mechanism of ion coupling. Nature. 2006. ↩︎ ↩︎ ↩︎
Barton J, et al. NET inhibitors: From pharmacology to therapeutic utility. Handb Exp Pharmacol. 2013. ↩︎ ↩︎
Harrison J, et al. The norepinephrine transporter as a biomarker and therapeutic target in major depressive disorder. Biol Psychiatry. 2016. ↩︎ ↩︎
Weinshenker D. Norepinephrine and Parkinson's disease. Brain Res. 2008. ↩︎ ↩︎ ↩︎
Mravec B, et al. Locus coeruleus-norepinephrine in CNS function and pathology. Prog Neuropsychopharmacol Biol Psychiatry. 2011. ↩︎
Esler M, et al. The fate of the sympathetic nervous system in human sympathetic nerves. J Clin Invest. 1976. ↩︎
Goldstein DS, et al. Norepinephrine in human sympathetic nerves: Source, fate, and function. J Auton Nerv Syst. 1995. ↩︎
Sotak M, et al. Dysregulation of norepinephrine transporter in the locus coeruleus in Parkinson's disease. Brain Res. 2005. ↩︎ ↩︎
Kish D, et al. Norepinephrine transporter: A potential vulnerability factor for Parkinson's disease. Neuropharmacology. 2008. ↩︎
Rommelfanger KS, et al. Norepinephrine: The rediscovered target for Parkinson's disease. Neuropharmacology. 2007. ↩︎ ↩︎
Manaye K, et al. Locus coeruleus neuron loss and NE depletion in AD. J Neurochem. 2007. ↩︎
Fuller S, et al. Noradrenergic dysfunction in Alzheimer's disease. J Neurosci Res. 2010. ↩︎
Szot P, et al. NE transporter in AD: A protective factor?. Brain Res. 2005. ↩︎
German DC, et al. Norepinephrine and neurodegeneration in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2012. ↩︎
Hauck R, et al. Functional analysis of norepinephrine transporter gene variants in psychiatric disorders. Pharmacogenomics. 2010. ↩︎ ↩︎
Zanner R, et al. Norepinephrine transporter function and autism: A genetic risk factor affecting transporter expression. J Neurochem. 2010. ↩︎
Rhee M, et al. The norepinephrine transporter in attention-deficit hyperactivity disorder: Effects of stimulants. J Neurochem. 2011. ↩︎
O'Rourke M, et al. Clinical use of norepinephrine transporter PET in neuropsychiatry. J Nucl Med. 2014. ↩︎